The Effect of Blended Sensor Efficiency on Relieving the Heart's Inability to Increase Its Rate During Exercise

Chronotropic Incompetence Clinical Trial

— ABSOLVE CI  

Official title:

The impAct of Blended Sensor Optimization on resoLVing Chronotropic Incompetence: ABSOLVE CI

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01619800
• Other study ID #: 11-02-333-05
• Status: Terminated
• Phase: N/A
• First received: June 12, 2012
• Last updated: April 15, 2017
• Start date: March 2012
• Est. completion date: October 2013

Study information

• Verified date: April 2017
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this trial is to test the effect/benefit of a FDA approved blended pacemaker sensor which responds only by comparing physical activity, heart rate, and breathing rate; compared to the accelerometer pacemaker sensor which respond only by comparing physical activity and the heart rate in patients whose heart is unable increase its heart rate according to increase physical activity or demand (Chronotropic Incompetence). Only one pacemaker family will be used in this clinical trial whereas the "out of box" configuration is the blended sensor which can also be made to act only as an accelerometer.

Description:

Objective: The goal of this trial is to test the impact of individualized blended sensor optimization on chronotropic response, compared with accelerometer use alone, in patients with chronotropic incompetence who are planned to undergo permanent pacemaker (PPM) implantation.

Study Population: The study population will consist of patients who suffer from the heart's inability to increase its heart rate according to increased physical activity or demand (chronotropic incompetence). These patients are planned to undergo permanent pacemaker (PPM) implantation.

PRIMARY ENDPOINT: Improvement in chronotropic competence as defined as an increase in age-predicted maximum heart rate (APMHR) which is defined as 220 beats per minute (bpm) minus patient's age in years. Age-predicted heart rate reserve (APMHR) defined as APMHR minus patient's heart rate at rest. Observe the maximal heart rate during exercise test with decrease in oxygen consumption at each stage and also at peak effort.

SECONDARY ENDPOINT:

1. Quality of life.

2. Procedural safety as defined by the number of complications within 1week associated with the procedure.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: October 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or older

• Evidence of chronotropic incompetence on exercise or pharmacological stress test defined as the inability to achieve 85% or greater of Age-predicted heart rate reserve (APMHR)

• Legal status to give informed consent specific to state and national law.

• Planned for PPM implantation and meets current guidelines for PPM therapy.

Exclusion Criteria:

• Inability to give informed consent

• Inability to comply with the follow-up visit schedule.

• Unable to participate in stress testing (exercise or pharmacological).

• Previous PPM implantation

• A life expectancy of less than 12 months per physician discretion

• Enrolled in any concurrent study, without Boston Scientific written approval.

• Pregnancy

• Unstable chest pain

• Stroke within 30 days

• Heart attack within 90 days

• Stress Test Exclusion Criteria: No evidence of Chronotropic incompetence on exercise or pharmacological stress test, defined as the ability to achieve 85% or greater of APMHR.

Related Conditions & MeSH terms

• Chronotropic Incompetence

Intervention

Device:
• Blended Sensor Optimization (BSO)
At wound check (POD#1 and 1 Week F/U), histograms from device interrogation obtained from patients in the BSO group are assessed, and these patients undergo optimization. A hall walk and stair climbing exercise will be performed and MV optimized using trending data to hit the following targets: HR at Rest: 60 HR upon slow walking: 100 HR upon brisk walking: 115-120 HR upon climbing stairs: 130-135 Patients will undergo optimization, and be instructed that their device may have been optimized.
• Accelerometer Alone (AA)
Patients in the AA group will also undergo device interrogation, and will perform a hall walk and stair climbing exercise. Afterwards, these patients will undergo a sham optimization by placing the PPM interrogation laptop device over there pacemaker, and instructing the patients that their device may have been optimized.

Locations

Country	Name	City	State
United States	Icahn School of Medicine at Mount Sinai	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Vivek Reddy	Boston Scientific Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changed in Stress Test at 6 Months as Compared to Baseline	An Exercise or Dobumatime Stress Test to be performed to assess primary outcome measure.	baseline and 6 months